Database

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

Connor Consulting First in Middle East to Earn Oracle's Verified SAM Expertise, Bolstering Regional Presence

Retrieved on: 
Monday, March 25, 2024
Certification, Organization, SAAS, Investment, SAM, Database, Verified, Consultant, PAAS, Asset management

This recognition reinforces Connor Consulting's expertise in helping Middle Eastern businesses optimize their IT investments by effectively managing their Oracle software assets through the Verified SAM program.

Key Points: 
  • This recognition reinforces Connor Consulting's expertise in helping Middle Eastern businesses optimize their IT investments by effectively managing their Oracle software assets through the Verified SAM program.
  • Connor Consulting's Verified SAM certification solidifies their dedication to software asset management excellence and innovation in the Middle East.
  • "Earning the first Verified SAM Partner in the Middle East is a badge of honor for Connor Consulting," says Jay T. Buck, Global Vice President of Software Solutions.
  • For additional information or inquiries about how Connor Consulting can assist your organization in optimizing its software asset management strategy through the Verified SAM program, please contact [email protected]

Fauna Launches Distributed Document-Relational Database On Google Cloud Marketplace

Retrieved on: 
Thursday, March 21, 2024
Cloud, Dai, Google Cloud, Organization, Database, Software as a service, ISV, Internet of things, SAN, Cloud storage, B2C, Google Compute Engine, Booth, API, Engineering, Mobile phone

The Google Cloud Marketplace listing puts Fauna directly in front of global enterprises that require both the flexibility of documents and the power of a relational ACID-compliant database that scales across regions, clouds, or the globe. As enterprises accelerate investment in transactional edge, B2B, and B2C multi-tenant SaaS and generative AI applications, the foundational infrastructure powering these applications, especially the database, is critical in fulfilling scalability, performance, and global data residency compliance requirements. Fauna delivers an intuitive developer experience with a seamlessly scalable distributed architecture that provides strong consistency, low millisecond latency, and high availability -- all delivered as a secure cloud API with zero operations required.

Key Points: 
  • SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Fauna , the distributed document-relational database delivered as a cloud API, today announced the availability of its database on Google Cloud Marketplace.
  • Now, Google Cloud and Fauna customers can procure, activate, and manage the Fauna database directly through their Google Cloud account, streamlining integrations and workflows while unifying resourcing and billing.
  • Customers utilizing both Google Cloud and the Fauna database will now enjoy a streamlined experience through their Google Cloud accounts, with Fauna usage, management, and billing now unified in their Google Cloud contracts.
  • “We are excited about the deepening relationship between Fauna and Google Cloud to make leveraging these technologies together even easier.”
    “Bringing Fauna to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the Fauna database on Google Cloud's trusted, global infrastructure," said Dai Vu, Managing Director, Marketplace & ISV GTM Programs at Google Cloud.

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, March 20, 2024
23andMe, Genetics, Patient, SAN, Database, Research, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.
  • The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world's largest recontactable database of de-identified human genetic and phenotypic information.
  • This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years.
  • “We are excited to be underway in our study of ‘1473, and we are grateful to the patients participating in this trial.”

Bradford County, PA to Transition to Online Sheriff’s Sales

Retrieved on: 
Tuesday, March 19, 2024
REO, Database, Sale, Commonwealth, Bid4Assets, Auction

By moving online, the sheriff’s office intends to streamline the auction process and increase accessibility by allowing all participants to bid remotely.

Key Points: 
  • By moving online, the sheriff’s office intends to streamline the auction process and increase accessibility by allowing all participants to bid remotely.
  • Bid4Assets has recently hosted successful online foreclosure sales for multiple sheriff’s offices in Pennsylvania, including Montgomery, Monroe, Berks, Adams and Philadelphia Counties.
  • We’re thrilled to see Bradford County making this transition.”
    Bid4Assets was founded in 1999 and conducted the first online tax sale and the first online federal forfeiture auction in the U.S., both in 2000.
  • Bid4Assets pioneered the first online sheriff’s sale in the Commonwealth of Pennsylvania in 2020.

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

Retrieved on: 
Monday, March 18, 2024
Inflammation, Health, Conference, Database, Patient, Serology, Research, Lymphocyte, Gastrointestinal disease, Doctor of Philosophy, CED, First wave, Abstract, Gastroenterology, DDW, Coeliac disease, IEL

BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024, in Washington, D.C.

Key Points: 
  • “The abstracts accepted for presentation at DDW 2024 showcase significant advancements in the field of gastroenterology, particularly in the precision diagnosis and management of celiac disease through the innovative VCIEL scale that our team has developed,” stated James Sapirstein, Chairman and CEO of First Wave BioPharma.
  • Details on the presentations are as follows:
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma
    Jack Syage, PhD.
  • President & Chief Operating Officer, First Wave BioPharma

Kinetica Launches Generative AI Solution for Real-Time Inferencing Powered by NVIDIA AI Enterprise

Retrieved on: 
Monday, March 18, 2024
Synthetic media, Database, SQL, RAG, SAN, AI, Table, Access control, Senior, LLM, Telemetry, API, NVIDIA

Kinetica’s solution — powered by the NVIDIA NeMo, part of the NVIDIA AI Enterprise software platform, and NVIDIA accelerated computing infrastructure — addresses all of these concerns.

Key Points: 
  • Kinetica’s solution — powered by the NVIDIA NeMo, part of the NVIDIA AI Enterprise software platform, and NVIDIA accelerated computing infrastructure — addresses all of these concerns.
  • This powerful combination enables enterprises to instantly enrich their generative AI applications with domain-specific analytical insights, derived directly from the latest operational data.
  • “Kinetica uses the NVIDIA AI Enterprise software platform and accelerated computing infrastructure to infuse real-time data into LLMs, helping customers transform their productivity with generative AI.”
    Kinetica’s real-time generative AI solution removes the requirement for reindexing vectors before they are available for query.
  • For instance, in telcos, Kinetica’s generative AI solution can be used to explore and analyze pcap traces in real-time.

Dr. Ralph Thomas and Andrew Cardno Announce the Upcoming Release of their Tenth Book: "The Math That Gaming Made (Compendium)"

Retrieved on: 
Friday, March 15, 2024
Convention, SAN, Education, Knowledge, Marketing, Database, Research, Compendium, Environment, Metamorphosis (Hilary Duff album), IGA, Toy

This milestone edition promises to provide a comprehensive understanding of gaming dynamics and database marketing, delivering valuable insights for professionals in the industry.

Key Points: 
  • This milestone edition promises to provide a comprehensive understanding of gaming dynamics and database marketing, delivering valuable insights for professionals in the industry.
  • This compendium is the result of over 15 years of writing, demonstrating a commitment to share and innovate with the industry.
  • "The Math That Gaming Made, 10th Edition" delves deep into the intricacies of gaming, offering updated content and innovative additions.
  • Dr. Ralph Thomas expresses his satisfaction with the latest edition, stating, "This 10th edition is the result of years of dedicated research.

TGGI and Hong Kong-based Zhongneng Aoyin Capital jointly launched an AI Chinese medicine platform

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Database, AI, Hope, TCM

Universal Group used 1% of the company's shares for a total of 1000,000,000 shares in exchange for 3.5% of the shares of Hong Kong Aoyin Capital.

Key Points: 
  • Universal Group used 1% of the company's shares for a total of 1000,000,000 shares in exchange for 3.5% of the shares of Hong Kong Aoyin Capital.
  • A wholly-owned subsidiary of Hong Kong Zhongneng Aoyin Capital is Zhongneng Aoyin Digital Security Guard (Shenzhen) Technology Co., Ltd.
  • As Chinese traditional medicine culture becomes more and more popular and applied around the world, TGGI and Hong Kong-based Zhongneng Aoyin Capital will jointly launch an AI traditional Chinese medicine platform in the near future to collect human health data through smart wearable devices and then upload the relevant data to AI The TCM platform conducts real-time analysis and issues TCM diagnosis and treatment suggestions, providing each user with 24-hour accompanying TCM doctors.
  • The arrival of AI will bring more convenience to mankind, and the emergence of the AI Chinese medicine platform will also bring new hope and new sunshine for the well-being of the world through Eastern medicine

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Retrieved on: 
Thursday, March 14, 2024
Research, Database, Gene expression, Disease, Patient, Accounting, OLE, Insurance, Ataxia, Clinical trial, Skin, Therapy, Safety, Pharmacokinetics, Interim, FA, FDA, BLA, Pharmaceutical industry

BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.

Key Points: 
  • BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.
  • Nomlabofusp was generally well-tolerated and demonstrated dose-dependent increases in skin and buccal cell frataxin levels.
  • Research and development expenses for the fourth quarter of 2023 were $10.6 million compared to $7.2 million for the fourth quarter of 2022.
  • General and administrative expenses for the fourth quarter of 2023 were $3.5 million compared to $3.2 million for the fourth quarter of 2022.